Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype

Cancer

Volumn 117, Issue 22, 2011, Pages 5058-5066

  Hernandez Ilizaliturri, Francisco J ^a   Deeb, George ^a   Zinzani, Pier L ^b   Pileri, Stefano A ^b   Malik, Farhana ^a   MacOn, William R ^c   Goy, Andre ^d   Witzig, Thomas E ^c   Czuczman, Myron S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Division of Cardiovascular Surgery   (United States)

^d HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

diffuse large B cell lymphoma; germinal center B cell like lymphoma; Hans algorithm; lenalidomide; nongerminal center B cell like lymphoma; relapsed refractory

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GERM CELL TUMOR; HUMAN; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; PATIENT CODING; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GERMINAL CENTER; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 80053502780     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26135     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503-511. (Pubitemid 30082188)
3. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 1937-1947. (Pubitemid 34651353)
4. Staudt LM,. Gene expression profiling of lymphoid malignancies. Annu Rev Med. 2002; 53: 303-318. (Pubitemid 34177883)
5. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103: 275-282. (Pubitemid 38029949)
6. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol. 2006; 208: 714-723.
7. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003; 101: 78-84. (Pubitemid 36025890)
8. Galustian C, Dalgleish A,. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother. 2009; 10: 125-133.
9. Chanan-Khan AA, Cheson BD,. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008; 26: 1544-1552.
10. Goy A,. New directions in the treatment of mantle cell lymphoma: an overview. Clin Lymphoma Myeloma. 2006; 7 (suppl 1): S24-S32.
11. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008; 26: 4952-4957.
12. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011 Jan 12 [Epub ahead of print].
13. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005; 11: 5984-5992. (Pubitemid 41170330)
14. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008; 140: 36-45. (Pubitemid 350233246)
15. Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001; 276: 22382-22387.
16. Zhu D, Corral LG, Fleming YW, et al. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008; 57: 1849-1859.
17. Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009; 114: 4713-4720.
18. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
19. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586. (Pubitemid 350002966)
20. Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005; 106: 3183-3190. (Pubitemid 41565917)
21. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002; 8: 68-74. (Pubitemid 34101731)
22. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of 6 genes. N Engl J Med. 2004; 350: 1828-1837. (Pubitemid 38917249)
23. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including 1 characterized by host inflammatory response. Blood. 2005; 105: 1851-1861. (Pubitemid 40731764)
24. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359: 2313-2323.
25. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007; 109: 4930-4935. (Pubitemid 46827791)
26. Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, et al. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol. 2009; 22: 1094-1101.
27. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009; 113: 6069-6076.
28. Davis RE, Staudt LM,. Molecular diagnosis of lymphoid malignancies by gene expression profiling. Curr Opin Hematol. 2002; 9: 333-338. (Pubitemid 34596878)
29. Costa LJ, Feldman AL, Micallef IN, et al. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol. 2008; 142: 404-412. (Pubitemid 351962182)
30. Mittrucker HW, Matsuyama T, Grossman A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997; 275: 540-543. (Pubitemid 27051911)
31. Uranishi M, Iida S, Sanda T, et al. Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy. Leukemia. 2005; 19: 1471-1478. (Pubitemid 41136344)
32. Calame KL,. Plasma cells: finding new light at the end of B cell development. Nat Immunol. 2001; 2: 1103-1108. (Pubitemid 33130143)
33. Johnson K, Calame K,. Transcription factors controlling the beginning and end of B-cell differentiation. Curr Opin Genet Dev. 2003; 13: 522-528. (Pubitemid 37204930)